Related Experiment Video
Updated: Oct 11, 2025
23:33
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
83.9K
Anticoagulant Treatment Regimens in Patients With Covid-19: A Meta-Analysis
Anselm Jorda1, Jolanta M Siller-Matula2,3, Markus Zeitlinger1
1Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
Clinical Pharmacology and Therapeutics
|December 4, 2021
Summary
Higher-dose anticoagulation for COVID-19 did not reduce mortality compared to prophylactic doses. While it decreased thromboembolic events, it increased major bleeding risks, showing no survival benefit for routine use.
Area of Science:
- Medical Research
- Clinical Trials
- Pharmacology
Background:
- Coronavirus disease 2019 (COVID-19) is linked to a hypercoagulable state.
- Hypotheses suggest higher-dose anticoagulation may be more effective than prophylactic doses for COVID-19 treatment.
Purpose of the Study:
- To evaluate the efficacy and safety of higher-dose anticoagulation versus prophylactic-dose anticoagulation in COVID-19 patients.
- To compare risks of death, thromboembolic events, and major bleeding between different anticoagulation strategies.
Main Methods:
- Meta-analysis of ten randomized controlled open-label trials.
- Inclusion of 5,753 patients diagnosed with COVID-19.
- Comparison of higher-dose (therapeutic and intermediate) versus prophylactic-dose anticoagulation.
Main Results:
- No significant difference in the risk of death or net adverse clinical events between higher-dose and prophylactic anticoagulation.
- Higher-dose anticoagulation reduced thromboembolic events but significantly increased major bleeding risk.
- No survival benefit observed for higher-dose anticoagulation in critically ill, noncritically ill, or patients with elevated d-dimer levels.
Conclusions:
- Current evidence does not support the routine use of higher-dose anticoagulation (therapeutic or intermediate) in COVID-19 patients.
- The increased risk of major bleeding outweighs the benefits of reduced thromboembolic events without a clear survival advantage.
- Further research may be needed to identify specific patient subgroups who could benefit from higher-dose anticoagulation.
More Related Videos
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
55
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
55
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.4K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.4K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.0K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.0K
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
68
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
68
01:18Endocarditis III: Medical Management
41
Infective endocarditis management involves a multifaceted approach encompassing infection prevention, lifestyle modifications, pharmacological therapy, and surgical management.Infection Prevention:Hand Hygiene: Thorough handwashing is crucial to prevent the spread of infection. Hand hygiene should be performed regularly, especially before and after using the restroom.Oral Hygiene: Good oral hygiene is essential. It includes brushing teeth immediately after waking up and before bed, flossing...
41
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
734
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
734